PRINCETON, N.J.—2022年5月5日– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2022. First Quarter Highlights: Revenue was $81.6 million, compared to $66.7 million in the first quarter of 2021, representing growth of 22% over the first quarter of 2021. Excluding Pinnacle … Continued
2022年5月3日ニュージャージー州プリンストン - バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Bank of America 2022 Healthcare ConferenceDate and Time: Tuesday, May 10 at 3:00 p.m. ET Citi’s Biopharma Virtual Co-Panel DayDate and Time: Wednesday, May 18 at 10:00 a.m. … Continued
PRINCETON, N.J.— 2022年4月20日– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2022 after the market close on Thursday, May 5th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in … Continued
PRINCETON, N.J.—2022年3月1日– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2021 and updated guidance for 2022. Fourth Quarter Highlights: Revenue was $75.3 million, compared to $64.6 million in the fourth quarter of 2020, representing growth of 17% over the … Continued
Affirms the advancements of innovative biosimulation technology and its growing impact in R&D PRINCETON, N.J.— 2022年2月23日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has licensed Certara’s Immunogenicity (IG) Simulator to research and evaluate immunogenicity in protein-based therapeutics. Certara’s IG Simulator … Continued
Asserts Certara’s leadership in advancing the development and approval of new drugs for patients PRINCETON, N.J.— 2022年2月15日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Review (CDER) were received … Continued
PRINCETON, N.J.— 2022年2月8日– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2021 after the market close on Tuesday, March 1st, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. … Continued
FDA holds more than 400 SimcypTM and PhoenixTM software licenses across 12 divisions and offices PRINCETON, N.J.— 2021年12月21日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has renewed and expanded its licenses of Certara’s proprietary biosimulation software, with more than 400 … Continued
New metrics and analytics capabilities enable informed decision making for biopharmaceutical clients PRINCETON, N.J., Dec. 13, 2021 — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced the feature release of Pinnacle 21 Enterprise 5.1.0, which updates the Company’s flagship software for preparing clinical trial data for biosimulation and regulatory submission. “With today’s … Continued
ニュージャージー州プリンストン - 2021年12月8日: バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, will host an Investor Day on 2021年12月15日 (水曜日) from 3:00 PM to 6:00 PM ET in New York City. Certara’s management team will provide updates on the Company’s strategy, differentiated software and technology-driven services, and financial guidance for … Continued
